ICON Public Limited (NASDAQ:ICLR) Receives Average Rating of “Moderate Buy” from Brokerages

ICON Public Limited (NASDAQ:ICLRGet Rating) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $280.40.

ICLR has been the subject of several recent analyst reports. Citigroup dropped their target price on ICON Public from $315.00 to $290.00 and set a “buy” rating for the company in a research report on Friday, July 8th. Deutsche Bank Aktiengesellschaft boosted their target price on ICON Public from $285.00 to $295.00 in a research report on Friday, July 29th. Barclays dropped their target price on ICON Public from $250.00 to $245.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 13th. Robert W. Baird restated a “buy” rating and set a $285.00 target price on shares of ICON Public in a research report on Friday, May 13th. Finally, William Blair restated an “outperform” rating on shares of ICON Public in a research report on Thursday, July 28th.

Hedge Funds Weigh In On ICON Public

A number of large investors have recently bought and sold shares of ICLR. Desjardins Global Asset Management Inc. bought a new position in ICON Public in the second quarter worth approximately $61,000. Assetmark Inc. raised its stake in ICON Public by 177.3% in the second quarter. Assetmark Inc. now owns 477 shares of the medical research company’s stock worth $103,000 after buying an additional 305 shares in the last quarter. Steph & Co. raised its stake in ICON Public by 21.5% in the second quarter. Steph & Co. now owns 604 shares of the medical research company’s stock worth $131,000 after buying an additional 107 shares in the last quarter. Harbor Investment Advisory LLC grew its holdings in ICON Public by 380.2% in the second quarter. Harbor Investment Advisory LLC now owns 629 shares of the medical research company’s stock worth $136,000 after purchasing an additional 498 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in ICON Public by 14.5% in the second quarter. First Horizon Advisors Inc. now owns 673 shares of the medical research company’s stock worth $145,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 91.28% of the company’s stock.

ICON Public Trading Down 0.9 %

Shares of ICLR opened at $206.74 on Monday. The company’s fifty day moving average is $223.81 and its 200 day moving average is $226.33. ICON Public has a fifty-two week low of $196.34 and a fifty-two week high of $313.00. The stock has a market capitalization of $16.83 billion, a PE ratio of 82.04, a P/E/G ratio of 1.29 and a beta of 0.95. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.18 and a current ratio of 1.18.

ICON Public (NASDAQ:ICLRGet Rating) last released its earnings results on Wednesday, July 27th. The medical research company reported $2.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.34. The firm had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. ICON Public had a net margin of 2.77% and a return on equity of 10.54%. The business’s revenue was up 122.1% on a year-over-year basis. During the same quarter last year, the business earned $2.12 EPS. Sell-side analysts expect that ICON Public will post 10.61 earnings per share for the current fiscal year.

ICON Public Company Profile

(Get Rating)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Articles

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.